still seems to think they have a great deal. Listen again to the CC. These guys know way more than we small retail investors ever will know and just how they can use and sell Aristotle tests. If James wants to bring some US institutional investors on board while targeting the US market thats fine with me. The SP now puts more pressure on Care to sell Aristotle and the Avrt program to protect their investment. IMO
Dr Padman Vamadevan undertook a Natural Sciences degree at Queens’ College, Cambridge, and subsequently completed his medical degree on the fast-track programme at Guy’s, King’s and St Thomas’ School of Medicine in London. He subsequently secured an Academic Foundation training post at Guy’s & St Thomas’ Hospitals, during which he was seconded to Quintiles Drug Research Unit where he was involved in trial design and management and data analysis.
Following this, he was appointed as an Academic Clinical Fellow in Clinical Pharmacology at St George’s Hospital and during this period, published multiple peer-reviewed papers, whilst also receiving a travel fellowship to speak at the European Respiratory Society congress. Subsequently, he has taken up a variety of Haematological and Oncological posts at a variety of leading cancer institutions in London, which have afforded him significant relevant clinical experiance.
He has worked at the Care Oncology Clinic since 2016 and his familiarity with Biochemistry, Clinical Pharmacology, Clinical Research Studies and Oncology are consistent with the academic lineages that underpin the metabolic treatments offered by the clinic.